Cargando…

Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer

Primary cancer survivors have a higher risk of developing second primary thyroid cancer (SPTC). Patients with SPTC who survived primary malignancies, diagnosed from 1975 to 2016, were identified from the Surveillance, Epidemiology, and End Results (SEER) database (SEER 18 Registry). A total of 33,55...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussein, Mohammad, Mueller, Lauren, Issa, Peter P., Haidari, Muhib, Trinh, Lily, Toraih, Eman, Kandil, Emad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406053/
https://www.ncbi.nlm.nih.gov/pubmed/36009531
http://dx.doi.org/10.3390/biomedicines10081984
_version_ 1784774029523025920
author Hussein, Mohammad
Mueller, Lauren
Issa, Peter P.
Haidari, Muhib
Trinh, Lily
Toraih, Eman
Kandil, Emad
author_facet Hussein, Mohammad
Mueller, Lauren
Issa, Peter P.
Haidari, Muhib
Trinh, Lily
Toraih, Eman
Kandil, Emad
author_sort Hussein, Mohammad
collection PubMed
description Primary cancer survivors have a higher risk of developing second primary thyroid cancer (SPTC). Patients with SPTC who survived primary malignancies, diagnosed from 1975 to 2016, were identified from the Surveillance, Epidemiology, and End Results (SEER) database (SEER 18 Registry). A total of 33,551 cancer cases were enrolled in the final analysis. Individuals with a primary malignancy were at a significant 90% increased risk of developing SPTC (SIR = 1.90, 95%CI = 1.86–1.93, p < 0.05) compared to the general population. More than half (54.7%) of SPTC diagnoses were made in the first three years after primary cancer diagnosis, and the most aggressive presentations of SPTC occurred within the first year following malignancy. A latency trend analysis identified persistent high risk for development of SPTC after diagnosis of lymphoma, leukemia, soft tissue tumors, kidney, breast, and uterine cancer; elevated 10-year risk for most cancers such as salivary gland, melanoma, stomach, lung, colon, ovarian, pancreas, prostate, and bladder; and high 5-year risk after cancers such as larynx, oral, orbit, bone, small intestine, and liver. Our latency period model identifying risk according to each type of primary cancer may aid clinicians in identifying at-risk patients to be screened for thyroid cancer and guide them in developing a surveillance plan according to the latency period attributed to a patient’s primary cancer.
format Online
Article
Text
id pubmed-9406053
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94060532022-08-26 Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer Hussein, Mohammad Mueller, Lauren Issa, Peter P. Haidari, Muhib Trinh, Lily Toraih, Eman Kandil, Emad Biomedicines Article Primary cancer survivors have a higher risk of developing second primary thyroid cancer (SPTC). Patients with SPTC who survived primary malignancies, diagnosed from 1975 to 2016, were identified from the Surveillance, Epidemiology, and End Results (SEER) database (SEER 18 Registry). A total of 33,551 cancer cases were enrolled in the final analysis. Individuals with a primary malignancy were at a significant 90% increased risk of developing SPTC (SIR = 1.90, 95%CI = 1.86–1.93, p < 0.05) compared to the general population. More than half (54.7%) of SPTC diagnoses were made in the first three years after primary cancer diagnosis, and the most aggressive presentations of SPTC occurred within the first year following malignancy. A latency trend analysis identified persistent high risk for development of SPTC after diagnosis of lymphoma, leukemia, soft tissue tumors, kidney, breast, and uterine cancer; elevated 10-year risk for most cancers such as salivary gland, melanoma, stomach, lung, colon, ovarian, pancreas, prostate, and bladder; and high 5-year risk after cancers such as larynx, oral, orbit, bone, small intestine, and liver. Our latency period model identifying risk according to each type of primary cancer may aid clinicians in identifying at-risk patients to be screened for thyroid cancer and guide them in developing a surveillance plan according to the latency period attributed to a patient’s primary cancer. MDPI 2022-08-16 /pmc/articles/PMC9406053/ /pubmed/36009531 http://dx.doi.org/10.3390/biomedicines10081984 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hussein, Mohammad
Mueller, Lauren
Issa, Peter P.
Haidari, Muhib
Trinh, Lily
Toraih, Eman
Kandil, Emad
Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer
title Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer
title_full Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer
title_fullStr Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer
title_full_unstemmed Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer
title_short Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer
title_sort latency trend analysis as a guide to screening malignancy survivors for second primary thyroid cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406053/
https://www.ncbi.nlm.nih.gov/pubmed/36009531
http://dx.doi.org/10.3390/biomedicines10081984
work_keys_str_mv AT husseinmohammad latencytrendanalysisasaguidetoscreeningmalignancysurvivorsforsecondprimarythyroidcancer
AT muellerlauren latencytrendanalysisasaguidetoscreeningmalignancysurvivorsforsecondprimarythyroidcancer
AT issapeterp latencytrendanalysisasaguidetoscreeningmalignancysurvivorsforsecondprimarythyroidcancer
AT haidarimuhib latencytrendanalysisasaguidetoscreeningmalignancysurvivorsforsecondprimarythyroidcancer
AT trinhlily latencytrendanalysisasaguidetoscreeningmalignancysurvivorsforsecondprimarythyroidcancer
AT toraiheman latencytrendanalysisasaguidetoscreeningmalignancysurvivorsforsecondprimarythyroidcancer
AT kandilemad latencytrendanalysisasaguidetoscreeningmalignancysurvivorsforsecondprimarythyroidcancer